Cure Alzheimer's Fund Cure Alzheimer's Fund

Role of the Circulating Exerkine GPLD1 in Ameliorating Alzheimer’s Disease Pathology

2022, 2024

The research described in this proposal will investigate the beneficial effect of the exercise-induced, liver-derived blood factor Glycosylphosphatidylinositol-Specific Phospholipase D1 (GPLD1) on the brain vasculature as a critical mediator in combating drivers of Alzheimer’s disease. This study will delineate cellular and molecular mechanisms underlying the benefits of systemic GPLD1 in restoring cognitive function and ameliorating Alzheimer’s disease pathology in the hippocampus. The results from this study will have significant translational potential, positing GPLD1 as a novel therapeutic target to reverse functional impairments in Alzheimer’s disease.

Saul Villeda Studies of Alternative Neurodegenerative Pathways Translational

Funding to Date

$402,500

Focus

Studies of Alternative Neurodegenerative Pathways, Translational

Researchers

Saul Villeda, B.S., Ph.D.

Related Content:


Evaluating the Contribution of TDP-43 Dysfunction and Cryptic Mis-Splicing to Alzheimer’s Disease Pathogenesis Leonard Petrucelli 2024-10-31 Role of Psychosocial Stress in Alzheimer’s Disease Filip Swirski 2024-10-31 Pre-Clinical Testing of CDK4/6 Inhibitors as a Therapeutic Strategy in Alzheimer’s Disease Using Alzheimer’s Disease Tauopathy Mouse Model Peter Sicinski 2024-09-24 Dysregulation of Signaling on Post Synaptic Density Scaffolds in Alzheimer’s Disease Alexandra C. Newton 2024-07-29 Novel Artificial Intelligence (AI) Decodes Aging Neurons Andrew J. Holbrook Theodore Zwang 2024-07-23 2-Deoxyglucose and Its Analogs as Novel Therapeutics to Build Resilience to Alzheimer’s Disease Rajiv R. Ratan Theodore J. Lampidis 2024-07-23 The Role of Calcium Homeostasis in Axonal Spheroid Formation in Alzheimer’s Disease Jaime Grutzendler 2024-06-13 Brain Entry and Exit Consortium: Neuroinflammation at the Choroid Plexus in Alzheimer’s Disease Maria Lehtinen 2024-05-02